Grandy David K
Department of Physiology and Pharmacology, L334, School of Medicine, Oregon Health and Science University, Portland, OR 97239, United States.
Pharmacol Ther. 2007 Dec;116(3):355-90. doi: 10.1016/j.pharmthera.2007.06.007. Epub 2007 Jul 17.
Interest has recently been rekindled in receptors that are activated by low molecular weight, noncatecholic, biogenic amines that are typically found as trace constituents of various vertebrate and invertebrate tissues and fluids. The timing of this resurgent focus on receptors activated by the "trace amines" (TA) beta-phenylethylamine (PEA), tyramine (TYR), octopamine (OCT), synephrine (SYN), and tryptamine (TRYP) is the direct result of 2 publications that appeared in 2001 describing the cloning of a novel G protein-coupled receptor (GPCR) referred to by their discoverers Borowsky et al. as TA1 and Bunzow et al. as TA receptor 1 (TAR1). When heterologously expressed in Xenopus laevis oocytes and various eukaryotic cell lines, recombinant rodent and human TAR dose-dependently couple to the stimulation of adenosine 3',5'-monophosphate (cAMP) production. Structure-activity profiling based on this functional response has revealed that in addition to the TA, other biologically active compounds containing a 2-carbon aliphatic side chain linking an amino group to at least 1 benzene ring are potent and efficacious TA receptor agonists with amphetamine (AMPH), methamphetamine, 3-iodothyronamine, thyronamine, and dopamine (DA) among the most notable. Almost 100 years after the search for TAR began, numerous TA1/TAR1-related sequences, now called TA-associated receptors (TAAR), have been identified in the genome of every species of vertebrate examined to date. Consequently, even though heterologously expressed TAAR1 fits the pharmacological criteria established for a bona fide TAR, a major challenge for those working in the field is to discern the in vivo pharmacology and physiology of each purported member of this extended family of GPCR. Only then will it be possible to establish whether TAAR1 is the family archetype or an iconoclast.
最近,人们对一类受体重新燃起了兴趣,这类受体由低分子量、非儿茶酚类生物胺激活,这些生物胺通常作为各种脊椎动物和无脊椎动物组织及体液中的微量成分被发现。对由“痕量胺”(TA)β-苯乙胺(PEA)、酪胺(TYR)、章鱼胺(OCT)、辛弗林(SYN)和色胺(TRYP)激活的受体的这一重新关注,直接源于2001年发表的两篇论文,它们描述了一种新型G蛋白偶联受体(GPCR)的克隆,其发现者Borowsky等人将其称为TA1,Bunzow等人则称为TA受体1(TAR1)。当在非洲爪蟾卵母细胞和各种真核细胞系中进行异源表达时,重组的啮齿动物和人类TAR剂量依赖性地与腺苷3',5'-单磷酸(cAMP)生成的刺激偶联。基于这种功能反应的构效关系分析表明,除了TA之外,其他含有将氨基与至少一个苯环相连的2-碳脂肪族侧链的生物活性化合物,都是强效且有效的TA受体激动剂,其中最值得注意的有苯丙胺(AMPH)、甲基苯丙胺、3-碘甲状腺原氨酸、甲状腺原氨酸和多巴胺(DA)。在寻找TAR开始近100年后,到目前为止,在每一种被检测的脊椎动物基因组中都鉴定出了大量与TA1/TAR1相关的序列,现在称为TA相关受体(TAAR)。因此,尽管异源表达的TAAR1符合为真正的TAR确立的药理学标准,但该领域研究人员面临的一个主要挑战是,要弄清楚这个扩展的GPCR家族中每个所谓成员的体内药理学和生理学特性。只有到那时,才有可能确定TAAR1是家族原型还是异类。